O'Hara Montana, Janda Monika, McCarthy Alexandra L, Nicklin James, Walker Graeme, Obermair Andreas
Queensland Centre for Gynaecological Cancer, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia.
Gynecol Oncol Rep. 2021 Dec 22;39:100914. doi: 10.1016/j.gore.2021.100914. eCollection 2022 Feb.
The aim of the study was to obtain an in-depth understanding of the experience of women who received non-surgical treatment for endometrial adenocarcinoma (EAC) or endometrial hyperplasia with atypia (EHA). Enhanced understanding of women's experiences of non-surgical treatment is essential to inform counselling of the growing number of patients in this field.
Individual semi-structured interviews were conducted with 21 women who received conservative (non-surgical hormonal) treatment for early stage EAC or EHA using the levonorgestrel intrauterine device (LNG-IUD) as part of the feMMe trial (NCT01686126). All interviews were audiotaped and transcribed verbatim prior to content analysis.
Of the 21 women interviewed, ten received conservative treatment for early stage EAC and 11 received conservative treatment for EHA. Five overarching themes were identified: i) extensive information and support needs (e.g. understanding of how the LNG-IUD treatment worked); ii) gratitude for treatment choice and non-surgical options (e.g. avoidance of potential risks associated with surgery); iii) onco-fertility (e.g. desire to maintain reproductive potential); iv) patient experience of overweight and obesity related to EAC development (e.g. history of trauma and disordered eating, multiple unsuccessful weight loss attempts); and v) patient experience of treatment options and actual non-surgical treatment (e.g. desire for early referral to counselling services).
This qualitative investigation enabled novel insights into the treatment preferences and decision-making process of women with newly diagnosed EHA and EAC when offered non-surgical treatment options. These insights facilitate the development of pragmatic guidance and decision support tools that could be tested in future clinical trials.
本研究旨在深入了解接受子宫内膜腺癌(EAC)或非典型子宫内膜增生(EHA)非手术治疗的女性的经历。深入了解女性非手术治疗的经历对于为该领域日益增多的患者提供咨询至关重要。
对21名接受保守(非手术激素)治疗的早期EAC或EHA女性进行了个体半结构式访谈,这些女性使用左炔诺孕酮宫内节育器(LNG-IUD)作为feMMe试验(NCT01686126)的一部分。在进行内容分析之前,所有访谈都进行了录音并逐字转录。
在接受访谈的21名女性中,10名接受了早期EAC的保守治疗,11名接受了EHA的保守治疗。确定了五个总体主题:i)广泛的信息和支持需求(例如了解LNG-IUD治疗的工作原理);ii)对治疗选择和非手术方案的感激之情(例如避免与手术相关的潜在风险);iii)肿瘤生育力(例如希望维持生殖潜力);iv)与EAC发展相关的超重和肥胖患者经历(例如创伤和饮食失调史、多次减肥失败尝试);v)患者对治疗方案和实际非手术治疗的经历(例如希望尽早转诊至咨询服务)。
这项定性研究对新诊断的EHA和EAC女性在提供非手术治疗方案时的治疗偏好和决策过程提供了新的见解。这些见解有助于开发实用的指导和决策支持工具,可在未来的临床试验中进行测试。